SLU-PP-332 is sold as an "exercise in a pill". It is not a peptide — a 290-dalton synthetic molecule that switches on the estrogen-related receptors — and it sits in this catalogue because it is sold through the same vendors as research peptides, like 5-amino-1MQ and tesofensine.
Its dose record has a feature no other page in this cluster has: the people who invented the compound have published that it does not work by the route it is sold in. This page reports what the sources state and recommends nothing.
The published doses, all of them
| Dose | Route | Duration | Where | Source |
|---|---|---|---|---|
| 30 mg/kg | Intraperitoneal, single | Plasma and muscle sampled at 2 and 6 h | Mice | ACS Chemical Biology 2023 |
| 50 mg/kg | Intraperitoneal, twice daily | 7, 10 and 15 days | Mice | ACS Chemical Biology 2023 |
| 25 mg/kg | Intraperitoneal, twice daily | Heart-failure model | Mice | Circulation 2024 |
| 25 mg/kg/day | Not stated in the insert | 8 weeks | 21-month-old mice | Cayman Chemical insert, citing the kidney-ageing study |
| Human doses | — | — | — | None published or registered |
Two details of the mouse work matter more than the numbers. The first is the route: intraperitoneal, an injection into the abdominal cavity that has no human equivalent in this market. The second is the vehicle: the Circulation methods prepared the compound at 5 mg/mL in 12% DMSO and 15% Cremophor in phosphate-buffered saline. Cayman's own insert explains why — SLU-PP-332 is sparingly soluble in DMSO at 1 to 10 mg/mL, slightly soluble in ethanol at 0.1 to 1 mg/mL, and the insert gives no figure for water.
A compound that needs a surfactant and a solvent to reach 5 mg/mL is a formulation problem before it is a dosing question.
The developers' own verdict on the oral route
In January 2026 the group behind the molecule published a paper in the Journal of Pharmacology and Experimental Therapeutics introducing SLU-PP-915. The reason it exists is stated in the abstract: SLU-PP-332 "improves aerobic performance in mice but lacks oral bioavailability", while 915 "is orally bioavailable and exhibits potent in vivo exercise mimetic activity".
That sentence is the most consequential dosage fact available about SLU-PP-332, because the market sells it as a 50 mg oral tablet and in oral capsules from 250 mcg upward.
It also has a commercial context worth stating: the 915 paper's conflict-of-interest statement records that the compound is covered by Saint Louis University intellectual property with the senior author as an inventor, and that he holds stock in two companies developing ERR agonists. The statement is in the paper; it does not bear on whether the oral-bioavailability finding is correct, and no published source contradicts it.
The retail figures, and how far apart they are
| Source | Figure stated | Form | Date read |
|---|---|---|---|
| Supplier knowledge page | 10–20 mg daily, orally | Capsules 250 mcg to 20 mg; tablets; 5 mg injection vial | 29 Jan 2026 |
| Vendor dosing guide | 10–50 mg daily, in beginner / intermediate / advanced tiers | Capsules | Read 17 Sep 2026 |
| Protocol site | Under 1.5 mg to 100 mg daily as "community patterns" | 50 mg tablet, 60-count | Read 17 Sep 2026 |
| Same protocol site | ~650 mg daily as a scaling ceiling, shown to illustrate the gap | 13 tablets | Read 17 Sep 2026 |
Three things follow. The strengths on sale span 200-fold — 250 mcg to 50 mg — for a molecule with no human dose record. The figures disagree with each other by a factor of thirty at the extremes. And the supplier page asserting "excellent oral bioavailability" states the opposite of the developers' published finding, in the same month that finding appeared.
The protocol site is the most transparent of the three: it says plainly that every published in vivo dose is a mouse dose and that no human titration schedule, pharmacokinetic study or safety margin exists. It then prints four dosing patterns anyway.
What the published work does show
The preclinical file is coherent and genuinely interesting, which is why the retail pages have something to point at. In mice, the compound induces the gene programme of acute aerobic exercise, increases oxidative muscle fibres and mitochondrial protein, reduces fat mass in diet-induced obesity, and improves running distance and time to exhaustion. A 2024 Circulation paper reports benefit in heart-failure models; a 2023 American Journal of Pathology paper reports effects in ageing kidneys. Ten papers, all preclinical.
Two of the ten are anti-doping analytical chemistry, published in 2026 in Drug Testing and Analysis and Rapid Communications in Mass Spectrometry, describing how to identify the compound's metabolites in a sample. Detection methods for athletes exist before any human trial does.
And the human-cell work that does exist is not administration: a 2025 Frontiers in Physiology pilot took muscle biopsies from 20 women during hip surgery and treated cultured myoblasts with SLU-PP-332. Human tissue, in a dish.
What is not established
- No human dose, anywhere, by any route.
- No human pharmacokinetics, so no basis for converting a mouse figure.
- No registration, so no protocol and no safety monitoring in people.
- No oral bioavailability — the developers state the compound lacks it.
- No aqueous solubility figure in the supplier insert, which is the practical obstacle behind the vehicle used in every animal study.
- No published origin for the 10 mg, 20 mg, 50 mg or 100 mg retail figures.
What a reader can check in five minutes
- Read the January 2026 JPET abstract and find the phrase "lacks oral bioavailability".
- Open Cayman Chemical's insert and read the solubility line.
- Search ClinicalTrials.gov for SLU-PP-332 and count the registrations.
- Compare two vendors' stated daily figures and note the factor between them.
- Ask any page quoting a human figure which study it came from, and by which route.
Related on this site
Peptide Lexicon's SLU-PP-332 entry covers what the compound is and what the ten papers found. On this site, 5-amino-1MQ is the other non-peptide sold as a metabolic capsule with no human data, and how to read a dosing claim sets out the checks that catch a figure scaled out of an animal study. Every dose record here is indexed on the peptide dosage chart.
Sources and dates
Opened 17 September 2026: PubChem CID 5338394; PubMed through the NCBI E-utilities for SLU-PP-332 (10 records, all abstracts retrieved), including PMID 41421047 (JPET, January 2026, doi:10.1016/j.jpet.2025.103787), PMID 36988910 (ACS Chemical Biology 2023), PMID 37961903 (Circulation 2024), PMID 37717940 (American Journal of Pathology 2023), PMID 40692696 (Frontiers in Physiology 2025) and PMID 42024694 (Revista Medica de Chile, February 2026); the PubMed Central full texts of the ACS Chemical Biology and Circulation papers for their dosing and vehicle methods; Cayman Chemical's product insert for item 41719; the ClinicalTrials.gov v2 API (no registrations); and three retail or protocol pages stating oral figures, dated 29 January 2026 and read today. Corrections go to the contact page.